Literature DB >> 3744727

Time domain analysis of VEPs. Detection of waveform abnormalities in multiple sclerosis.

D Urbach, M Gur, H Pratt, R Peled.   

Abstract

Visual evoked potentials (VEPs) are a useful tool in the diagnosis of multiple sclerosis. To improve their diagnostic power in the early stages of the disease, the VEP shape, as well as its latency, were considered. The Karhunen-Loeve expansion (KLE) was used because it affords an unique advantage in classifying the VEPs by their shape, and gives a well-defined criterion based on similarity to the normative prototype. Using this criterion, it was possible to quantitatively define normative limits of waveform. We were also able to detect early changes in VEPs recorded from suspected multiple sclerosis patients. KLE promises to enable classification of waveforms in early stages of the pathology, when peak-latency comparisons are the least effective.

Entities:  

Mesh:

Year:  1986        PMID: 3744727

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  3 in total

1.  Detection of hidden visual loss in multiple sclerosis. A comparison of pattern-reversal visual evoked potentials and contrast sensitivity.

Authors:  M J Leys; C M Candaele; A F De Rouck; J V Odom
Journal:  Doc Ophthalmol       Date:  1991       Impact factor: 2.379

2.  Evoked potentials as a biomarker of remyelination.

Authors:  Moones Heidari; Abigail B Radcliff; Gillian J McLellan; James N Ver Hoeve; Kore Chan; Julie A Kiland; Nicholas S Keuler; Benjamin K August; Dylan Sebo; Aaron S Field; Ian D Duncan
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-16       Impact factor: 11.205

3.  Crystal structure of Drosophila Piwi.

Authors:  Sonomi Yamaguchi; Akira Oe; Kazumichi M Nishida; Keitaro Yamashita; Asako Kajiya; Seiichi Hirano; Naoki Matsumoto; Naoshi Dohmae; Ryuichiro Ishitani; Kuniaki Saito; Haruhiko Siomi; Hiroshi Nishimasu; Mikiko C Siomi; Osamu Nureki
Journal:  Nat Commun       Date:  2020-02-12       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.